RT Journal Article
T1 Effect of a Ropy Exopolysaccharide-Producing Bifidobacterium animalis subsp. lactis Strain Orally Administered on DSS-Induced Colitis Mice Model.
A1 Hidalgo-Cantabrana, Claudio
A1 Algieri, Francesca
A1 Rodriguez-Nogales, Alba
A1 Vezza, Teresa
A1 Martínez-Camblor, Pablo
A1 Margolles, Abelardo
A1 Ruas-Madiedo, Patricia
A1 Gálvez, Julio
K1 Bifidobacterium
K1 DSS-colitis
K1 exopolysaccharide
K1 immune modulation
K1 mouse model
K1 mucoid
K1 ropy
AB Exopolysaccharide (EPS)-producing bifidobacteria, particularly Bifidobacterium animalis subsp. lactis strains, are used in the functional food industry as promising probiotics with purported beneficial effects. We used three isogenic strains of B. animalis subsp. lactis, with different EPS producing phenotypes (mucoid-ropy and non-ropy), in order to determine their capability to survive the murine gastrointestinal tract transit, as well as to evaluate their role in improving clinical outcomes in a chemically-induced colitis model. The three strains were able to survive in the intestinal tract of C57BL/6J mice during the course of the intervention study. Furthermore, the disease activity index (DAI) of the animal group treated with the ropy strain was significantly lower than of the DAI of the placebo group at the end of the treatment. However, no significant differences were found among the three strains. The analysis of several immune parameters, such as TNFα and IL-10 quantified in blood plasma and lymphocyte populations enumerated in mesenteric nodes, showed some significant variations among the four experimental animal groups. Remarkably, a higher capability of the ropy strain to increase regulatory T-cells in mesenteric lymphoid nodes was demonstrated, suggesting a higher ability of this strain to regulate inflammatory responses at mucosal level. Our data indicate that strains of B. animalis subsp. lactis producing EPS that confer a mucoid-ropy phenotype could represent promising candidates to perform further studies targeting intestinal inflammatory processes.
SN 1664-302X
YR 2016
FD 2016-06-09
LK http://hdl.handle.net/10668/10240
UL http://hdl.handle.net/10668/10240
LA en
DS RISalud
RD Apr 5, 2025